RARE raises PT to $58 on US accelerated approval of GENFLYCOS
RARE’s price target is raised to $58 from $45 following US accelerated approval of GENFLYCOS ahead of PDUFA, per Hammerstone MarketTalk at Citi.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.